Home: Publications: Forum Archives
MFF Forum, edition 4
What's
Inside:
From the Executive Director
Phototherapy for the Treatment
of CTCL/MF
Upcoming Patient Events
Photopheresis in the Treatment
of Early Stage CTCL
Dedications/Giving
Research Update
Home Phototherapy Units
PUVA Directory Available
CTCL Webcast Symposium
MFF
Hosts CTCL Symposium
The Mycosis Fungoides Foundation
(MFF) hosted its inaugural cutaneous T-cell lymphoma (CTCL) Symposium
on May 1, 2003 in Miami Beach, Florida. The symposium was part of the
International Investigative Dermatology (IID) 2003 meeting. The goal
of the symposium was to promote awareness, advance patient care and
facilitate research in CTCL. The symposium also provided an annual
venue to highlight new physicians and scientists to the field and new
advances in the treatment of CTCL.
This year’s program
consisted of four speakers. Dr. Lars French from the University of
Geneva spoke about how lymphocytes survive in the skin and what strategies
may prove useful to develop treatments that turn on "death" signals
to cancerous cells. Dr. Sam Hwang of the National Institutes of Health
spoke about the different molecules that make cells “sticky” and
that new biologic treatments that target these molecules in other skin
diseases, such as psoriasis, may have use in CTCL. Dr. Stuart Lessin
of the Fox Chase Cancer Center in Philadelphia spoke about the use
of Targretin® Gel in parapsoriasis, a condition that he considers
a precursor stage of CTCL and should be treated as a means of preventing
progression to CTCL.
Dr. Karen McGinnis, currently
dermatology resident at the University of Pennsylvania, was awarded
the MFF’s first Young Investigator Award for her work on treatment
of subcutaneous T-cell lymphoma. She presented several cases of subcutaneous
T-cell lymphoma, a rare and often aggressive form of cutaneous lymphoma,
which responded to Ontak®, a treatment FDA approved for CTCL. Based
on the excellent responses, she recommended the use of Ontak® as
a first choice for the treatment of subcutaneous T-cell lymphoma.
The symposium was very well
received, with over 150 international physicians and scientists in
attendance. The IID 2003 is the fourth joint meeting of the European
Society for Dermatological Research (ESRD), Japanese Society for Investigative
Dermatology (JSID) and the Society for Investigative Dermatology (SID).
Support for this year’s
CTCL Symposium was provided by educational grants from Ligand Pharmaceuticals,
Inc., Therakos, Inc. and ICN Pharmaceuticals, Inc. Judith Shea of the
MFF organized the symposium and Dr. Stuart Lessin served as moderator.
Plans are already underway for the 2nd annual CTCL Symposium to be
held at the annual meeting of the SID in 2004.